lncRNA Erbb4‑IR is downregulated in prostate carcinoma and predicts prognosis

Zhou,Jiuyun; Song,Quanbin; Liu,Xijuan; Ye,Hongli; Wang,Yusheng; Zhang,Lan; Peng,Shengjun; Qin,Hongping

doi:10.3892/ol.2020.11464

May-2020 Volume 19 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2020 Volume 19 Issue 5

Full Size Image

Article Open Access

lncRNA Erbb4‑IR is downregulated in prostate carcinoma and predicts prognosis

Authors:
- Jiuyun Zhou
- Quanbin Song
- Xijuan Liu
- Hongli Ye
- Yusheng Wang
- Lan Zhang
- Shengjun Peng
- Hongping Qin
View Affiliations / Copyright

Affiliations: Department of Urology, The First Hospital of The Chinese People's Liberation Army, Lanzhou, Gansu 730000, P.R. China, Department of Orthopedics, Gansu People's Hospital, Lanzhou, Gansu 730000, P.R. China, Reproductive Medical Center, 940 Hospital of The Joint Logistics Support Force of The Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China

Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 3425-3430
|
Published online on: March 16, 2020

https://doi.org/10.3892/ol.2020.11464
Expand metrics +

Abstract

Long non‑coding (lnc) RNA Erbb4-IR has been associated with diabetic renal injury; however, its roles in other diseases remain unknown. Therefore, the present study investigated the involvement of Erbb4‑IR in prostate carcinoma. Reverse transcription‑quantitative PCR was used to analyze gene expression in tissue samples collected from patients with prostate carcinoma. Overexpression experiments via cell transfection were performed to determine the association between Erbb4‑IR and microRNA (miR)‑21. Furthermore, Cell Counting Kit‑8 and cell apoptosis assays were performed to assess cell proliferation and apoptotic rate, respectively. The results revealed that Erbb4‑IR was downregulated in prostate carcinoma tissues compared with adjacent non‑cancerous tissues, and that low expression of Erbb4‑IR in tumor tissues was closely associated with poor survival. Furthermore, miR‑21 was upregulated in prostate carcinoma tissues compared with adjacent non‑cancerous tissues and was inversely associated with Erbb4‑IR expression in tumor tissues. In vitro cell experiments revealed that Erbb4‑IR overexpression resulted in the downregulation of miR‑21, while miR‑21 overexpression did not significantly affect the expression of Erbb4‑IR. Moreover, Erbb4‑IR overexpression increased apoptosis and inhibited the proliferation of prostate carcinoma cells. miR‑21 overexpression resulted in the opposite effect and attenuated the effects of Erbb4‑IR overexpression. Therefore, the results of the present study suggested that lncRNA Erbb4‑IR is downregulated in prostate carcinoma and may inhibit cancer development by downregulating miR‑21.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Lippi G, Montagnana M, Guidi GC and Plebani M: Prostate specific antigen-based screening for prostate cancer in the third millennium: Useful or hype? Ann Med. 41:480–489. 2009. View Article : Google Scholar : PubMed/NCBI
4	Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P and Allen NE; NHS Prostate Cancer Risk Management Programme, : Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: Systematic review and meta-analysis. Eur Urol. 48:386–399. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shand RL and Gelmann EP: Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol. 16:123–131. 2006. View Article : Google Scholar : PubMed/NCBI
6	Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
7	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
8	Gutschner T and Diederichs S: The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sun SF, Tang PMK, Feng M, Xiao J, Huang XR, Li P, Ma RCW and Lan HY: Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db mice by targeting miR-29b. Diabetes. 67:731–744. 2018. View Article : Google Scholar : PubMed/NCBI
10	Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, et al: miR-21: An oncomir on strike in prostate cancer. Mol Cancer. 9:122010. View Article : Google Scholar : PubMed/NCBI
11	Egner JR: AJCC cancer staging manual. JAMA. 304:1726–1727. 2010. View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Feng M, Tang PM, Huang XR, Sun SF, You YK, Xiao J, Lv LL, Xu AP and Lan HY: TGF-β mediates renal fibrosis via the Smad3-Erbb4-IR long noncoding RNA axis. Mol Ther. 26:148–161. 2018. View Article : Google Scholar : PubMed/NCBI
14	Colak S and Ten Dijke P: Targeting TGF-β signaling in cancer. Trends Cancer. 3:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
15	Pfeffer SR, Yang CH and Pfeffer LM: The role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015. View Article : Google Scholar : PubMed/NCBI
16	Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY: miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
18	Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, et al: miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol. 12:142012. View Article : Google Scholar : PubMed/NCBI
19	Kim YJ, Hwang SJ, Bae YC and Jung JS: miR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 27:3093–3102. 2009.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

lncRNA Erbb4‑IR is downregulated in prostate carcinoma and predicts prognosis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles